Octapharma AG - wilate - New generation VWF/FVIII concentrate 
EN: Navigation mit Access Keys
- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Kontakt
- [Alt + 4] - Sitemap
- [Alt + 5] - Suche
Developed to Set New
Standards in VWD Treatment
EN: Hauptnavigation
New generation VWF/Factor VIII concentrate
wilate product information
Valid in the following countries:
RMS: Germany
CMS: Austria, Belgium, Denmark, Finland, Luxemburg, Norway, Portugal, Sweden
Product Information Wilate USA - 10.11
 |
| Wilate SPC USA |
Canada PM French - January 2012
 |
| Canada PM French - January 2012 |
Canada PM English - January 2012
 |
| Canada PM - January 2012 |
Not current versions: available to provide information on filling sizes
 |
| PM French |
 |
| PM English |
wilate - New generation VWF/FVIII concentrate
High-purity human von Willebrand Factor (VWF)/Factor VIII concentrate with two independent virus inactivation steps (SD treatment and terminal dry heat at 100°C for 120 min) for the treatment of von Willebrand disease (VWD) and haemophilia A.
Available in vials of:
- 450 IU
- 900 IU
